Thank you for standing by, and good afternoon. Thank you for attending today's Owlet Q3 2024 Financial Results conference call. My name is Reagan, and I'll be your moderator today. All lines will be muted during the presentation portion of this call, with an opportunity for questions and answers at the end. If you would like to ask a question, please press star followed by one on your telephone keypad. I would now like to pass the conference over to our host, Jay Gentzkow, Vice President of Investor Relations. Jay, you may now proceed. Good afternoon, everyone, and thank you for joining us. Earlier today, Owlet released financial results for the Q3 ended September 30th, 2024. I'm pleased to be joined today by Kurt Workman, Owlet's Co-founder and CEO, Jonathan Harris, President and Chief Revenue Officer, and Amanda Twede Crawford, our CFO. Before we begin, please note that our financial results press release and presentation slides referred to on this call are available under the Events and Presentations section of our Investor Relations website at investors.owletcare.com. This call is also being webcast live with a link at the same website. The webcast and accompanying slides will be available for replay for 12 months following this call. The content of today's call is the property of Owlet. It cannot be reproduced or transcribed without our prior consent. Before we begin, I'd like to refer you to our safe harbor disclaimer on slide three of the presentation. Today's discussion will contain forward-looking statements based on the company's current views and expectations as of today's date. These statements are only predictions and are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, those described in our most recent filings with the SEC and in the risk factors section of our annual report on Form 10-K for the fiscal year ended December 31st, 2023. Please note that the company assumes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. With that, it's my pleasure to turn the call over to our CEO, Kurt Workman. Kurt? Thanks, Jay. Good afternoon, everyone, and thank you for joining us. I'm very proud of the team's efforts and execution to deliver another outstanding quarter following the FDA clearance of both BabySat and Dream Sock, including triple-digit year-over-year revenue growth, our sixth consecutive quarter of year-over-year gross margin expansion, and second consecutive quarter of Adjusted EBITDA profitability. Our performance throughout 2024 is a testament to the team's commitment and the passionate community of parents, health professionals, and partners that believe deeply in Owlet's mission. More and more parents are sharing in our vision of bridging technology, safety, and connected data to modern parenting, and that is enhancing our ability to execute on our growth strategies. I will begin on slide five. During the Q3 of 2024, we achieved net revenue of $22.1 million, representing strong year-over-year growth of 141%, driven primarily by global Dream Sock sales. We also saw continued gross margin expansion as third-quarter gross margins increased to 52%, up 1,590 basis points versus Q3 2023. This is our highest gross margin since going public in our sixth consecutive quarter of year-over-year gross margin expansion, a reflection of our ability to combine top-line growth with the operational improvements we've been driving the past couple of years. Third-quarter adjusted EBITDA was $0.6 million, an improvement of $6.1 million versus Q3 2023. Adjusted EBITDA for Q3 was both a record for Owlet and our second consecutive positive quarter, delivering on our commitment to maintain at or near adjusted EBITDA break-even. Moving to a few recent business highlights. I'm excited to share that we continue to see strong momentum with Amazon following our FDA clearance and shift to Amazon 1P as our distribution partner. As we shared last quarter, we had our most successful Amazon event at Prime Day in July. I'm excited to share that we followed up with a record Prime Big Deal Days event in October. Both events set company records for revenue and sell-through that Jonathan will touch on later in the call. Turning to BabySat. As a reminder, BabySat is our prescription monitor for high-risk babies. We continue to gain traction in the medical community, and we added five additional durable medical equipment manufacturers, or DMEs, to support additional expansion into the medical and healthcare channels. Owlet is in a unique position to be both a consumer as well as a medical-grade solution. As we further combine brand strength with increased awareness and adoption of BabySat, we expect to drive complementary growth for Dream Sock in the consumer channel. While it will take time for BabySat to scale in the medical market, there is a clear need for Owlet Technology as the first FDA-cleared wireless and wearable at-home solution to replace traditional bulky, wired, and expensive medical equipment. Finally, the rollout of Owlet's subscription service continues to make great progress. We successfully launched the beta version to thousands of caregivers in the Q3. Early results and feedback are off to a great start, including achieving a strong 85% retention rate after the first month, with approximately 60% of subscribers engaging as daily active users. We're excited to provide parents with health insights by leveraging our unmatched health and sleep data set. Subscription represents an exciting margin accretive growth driver, furthering Owlet's ability to define the category of infant health and safety. Finishing up on the Q1 earnings call, I outlined three strategic focus areas we believed were critical to increasing our growth opportunities and driving margin expansion and profitability. These were, first, drive continued adoption of Dream Sock globally. Second, expand medical and healthcare channels to offer an insurance reimbursement monitor. And third, transition Owlet into a service helping parents from infancy into the toddler years, thereby increasing LTV. We've made strong progress this year across these initiatives, and I'm proud of the team's efforts and commitments. I'll now turn the call over to Jonathan to walk through these focus areas in detail. Thanks, Kurt. I'm excited to start with our first strategic focus area, global adoption of Dream Sock, as we've made really incredible progress both in the U.S. and internationally. Domestically, the momentum since we received FDA clearance of Dream Sock continues to be outstanding. Dream Sock achieved another strong quarter of domestic sell-through growth at 55% versus prior Q3 of 2023. Customer satisfaction supports this growth as Owlet's blended NPS score across all products was slightly less than 70, and Dream Sock's NPS score leading the way at 74 in the Q3. Like we saw last quarter, returns continued to trend down to just above 4% compared to historical averages of 7%-9%, resulting from continued product improvement and customer satisfaction. Also, in the Q3, we increased press unique monthly visitors 110% quarter over quarter, in addition to 50 million organic social impressions with over one million engagements. We're also starting to translate Owlet's leading infant health brand and market enthusiasm into tangible market share gains. According to consumer research firm Circana, and Owlet's own data, Owlet's share of total dollars spent on baby monitors has increased to approximately 31% in the six months trending September 2024 versus 23% for the same period in 2023. Finally, as Kurt highlighted in his remarks, in July, we had our most successful Amazon Prime Day ever, setting records for revenue and sell-through units. We followed that impressive Prime Day event with a record-setting Prime Big Deal Days, with Dream Sock revenue up 75% and total sell-through revenue up 70% year-over-year. Our international adoption continues to be very strong, most notably in Europe and the United Kingdom, following the launch of Dream Sock with CE Medical Mark clearance in June. In the Q3 2024, we saw international revenue growth of 96% year-over-year, our third consecutive quarter of outsized growth. This includes shipping the medically certified Dream Sock to nine additional European markets this quarter, taking us to 26 countries in total across Europe and the United Kingdom. With approximately 140 million babies born worldwide every year and less than 3% currently having access to a Dream Sock, we believe that we are just scratching the surface of the international opportunity. In our second strategic focus area, we're making important strides following FDA approval of BabySat to expand our medical and healthcare channels to offer an insurance reimbursement monitor for high-risk babies. Adding distribution partners is critical to expanding Owlet's reach in the medical channel. In the Q3, we made important progress toward this strategy, expanding our distribution insurance coverage with five additional DMEs with national reach, all specialized in at-home maternity and newborn insurance offerings. In combination with our first successful DME signed earlier this year, AdaptHealth, these partnerships are expanding access to BabySat to caregivers throughout the United States, increasing opportunities for infants with medical necessities to conveniently and reliably leverage our innovative technologies. Insurance reimbursement is an important component of the medical strategy. Integrating with insurance plans will open up this category, reducing price barriers, increasing accessibility, and bringing BabySat safety and security to at-risk infants. Our insurance partners are also seeing the value in this technology. As an example, Cigna now recognizes BabySat as a single-patient technology and are reimbursing at a single-patient payment rate, making the process for reimbursement easier, quicker, and more palatable for our DME distributors. We are still very early in Owlet's medical and healthcare opportunity, and these channels will take time to grow. But we're investing the resources as we expect this category to be an important long-term growth driver, as well as being margin accretive to our overall business. Finally, as we continue to drive core growth in Dream Sock and build our medical channels with BabySat, the third important focus area and long-term growth driver will be Owlet's subscription service. As previously discussed, Owlet has a massive infant health and sleep data set, truly unmatched in the market today, and we're just beginning to unlock the potential of this opportunity. Specifically, Owlet's subscription service leverages our growing data set of trillions of heartbeats and millions of hours of sleep to help parents better assess their infants' health and sleep performance. Additionally, we believe a compelling subscription offering will extend the potential LTV per customer by increasing the value proposition of Dream Sock and Owlet Cams, extending us beyond just infant safety into infant health. We've made solid progress on our subscription initiative in the Q3, successfully launching the beta version of the service. We offered early access to thousands of caregivers, and from the sample, we saw over half the subscribers using Health Insights on a daily basis. Importantly, 85% of subscribers renewed. We're beginning to evolve this service and experiment with pricing, messaging, and features to optimize the value to our customers. But the early results and feedback we see are exciting, and we'll continue to update investors on our progress in the coming quarters. Now I'd like to turn the call over to Amanda to discuss the Q3 results and our outlook. Amanda, take it away. Thank you, Jonathan, and good afternoon, everyone. I'll begin on slide 12. Unless noted otherwise, I'll be comparing our Q3 2024 results to the Q3 of 2023. We wrapped up Q3 with another quarter of strong financial results. Owlet continues to execute on the financial goals we set out for in 2024. Net revenue in the Q3 was $22.1 million, a year-over-year increase of 141%. Revenue growth was driven primarily by sales of Dream Sock and Duo. As a reminder, in the Q3 of 2023, we signed a new distribution agreement with Amazon that offered more favorable terms and better execution. As a result, all sell-in revenue was pushed to the Q4 of 2023, which impacted the Q3 revenue growth when comparing year-over-year results and will impact year-over-year revenue growth in the Q4 2024 as well. Gross margin in the Q3 was 52.2%, an increase of 1,590 basis points year-over-year. This was our highest gross margin since going public and our sixth consecutive quarter of year-over-year gross margin expansion. The significant gross margin improvement reflects strong volume growth, favorable product mix towards Dream Sock, a reduction in return rates, lower direct product and fulfillment costs, and improved fixed cost absorption. Total operating expenses in the Q3 were $16.4 million, including stock-based compensation of $2.7 million, representing an increase of $5.2 million versus the same period last year. Operating costs increased primarily due to a $1.9 million non-cash impairment charge related to internally developed software. In addition, we had higher compensation expense, including accrued bonuses and severance-related expenses and higher marketing spend. This was partially offset by costs capitalized related to subscription app development. Operating loss in the Q3 was $4.8 million compared to $7.9 million in the same period last year. Net loss in the Q3 was $5.6 million versus $5.6 million in the same period last year. Q3 Adjusted EBITDA was a record for Owlet at $0.6 million, a significant improvement of $6.1 million compared to the same period last year. Top-line growth in combination with our focus on operating efficiency drove the increase in Adjusted EBITDA. Turning to our balance sheet, cash and cash equivalents as of quarter end September 30, 2024, were $21.5 million, up sequentially from $15.4 million in Q2 2024. In September, we successfully completed a follow-on equity offering, raising net proceeds of approximately $9.8 million. The capital raise provides additional funding to strengthen our cash position, grants us further balance sheet flexibility, and, just as important, engages a new group of supportive Owlet investors that we're hopeful will be long-term partners as we hit an exciting inflection point in our business. In combination with the equity offering, we also completed a debt restructuring for total proceeds of up to $35 million. The restructuring included upsizing our asset-based line of credit for up to $20 million, as well as refinancing our term loan for up to $15 million. This comprehensive debt restructuring improves the health of our balance sheet and increases our operational flexibility. At the end of Q3, we had drawn down $9.9 million on the line of credit and $7.5 million on the term loan. Now, turning to an update on our financial outlook. Given our performance in the seasonally strongest Q3 and our outlook for the balance of year, we now expect to land at the higher end of our initial 2024 guidance ranges. For the full year 2024, we now estimate net revenue of $74 million to $77.5 million, gross margins of 48%-49%, and Adjusted EBITDA loss of $5 million to $3 million. At the midpoint, this implies a guidance raise for the full year 2024 outlook that will be provided on the Q2 earnings call. As we look ahead to 2025, while it's early, we're expecting ongoing momentum across our business, including driving further growth in our core business, exciting opportunities with medical channels and subscription, and prioritizing profitability in the years ahead. We look forward to discussing 2025 expectations in more detail on our Q4 earnings call in March. With that, we will now take your questions. Operator, please open up the lines. Of course. We will now be moving into our Q&A session. So if you'd like to ask a question, please press star followed by one on your telephone keypad. To remove your question, press star followed by two. Again, to ask your question, press star one. As a reminder, if you are using a speakerphone, please remember to pick up your handset before asking your question. We will now briefly pause as questions are being registered. We have a question from Charles Wright of TD Cowen. Charles, your line is now open. Great. Thanks. Hi guys. This is Adam for Charles. Thanks for taking our questions. Wondering to start, if you can provide some insights on how you're seeing the state of the consumer environment and what, if any, changes you've seen over the course of the year in the health of the consumer environment. In addition, how this has translated, if at all, to maybe you've seen differentiated growth in certain channels over others this year. Hi. Thank you for that. We are seeing actually continued strong state of consumer environment. We believe that our FDA clearance in the United States and our CE Medical Mark across Europe and the UK are really resonating with our customers, and they're continuing to purchase our products in record numbers. So we see continued growth, and we're cautiously optimistic for the future. Got it. That's helpful. Thank you. Wondering if you can also discuss your manufacturing exposure geographically and how you're thinking about the potential impact now with a new administration and potential tariffs, the potential impact that might have on margins or whether, if there are, again, potential tariffs to come in place, would that drive you to consider potentially manufacturing elsewhere? Yeah. We do currently have our camera manufacturing in China, and then our Sock and Duo come through Thailand. We are well aware of the proposals that are coming through the new administration for tariffs and are looking strategically at our business. At Owlet, we can minimize that exposure. We are looking at possibly moving our manufacturing of the camera to Vietnam and just other options to minimize exposure. I would just add to that that the vast majority of our revenue comes from Sock and Duo. Those are our hero products and are not in China. There are several, in addition to what Amanda said, several ways that we're able to mitigate that ahead of those tariffs coming in. Lastly, I'd like to emphasize that our products are considered medical devices, the Duo and Sock. Up to this point, they have been excluded from any sort of tariffs, that they are a medical device. Very helpful. Thank you. And regarding BabySat, great to hear about Cigna reimbursing for BabySat. Can you remind us about the path forward and timeline, what it looks like for integrating with other major payers and regional payers? And additionally, how exposed, or sorry, how exposed now you are with multiple DMEs to the points of care that are key for BabySat, such as children's hospitals? Yeah, that's a great question. We continue to see additional DMEs come on board. We've had five additional that we've signed. Each of those have different relationships with reinsurers or insurers, and we're leveraging those relationships to drive that reimbursement to the patients. So each of them represents a slightly different channel of opportunity, all within the new mother space and/or the caregiver space. We're beginning to build relationships directly with NICUs and hospitals directly, and we're spending time and money integrating into those hospital networks. So we believe that we can really reach a larger majority of those children coming out of at-risk environments. Got it. And last one for us is on the international side, the opportunity that you guys see for BabySat there, if existing partners can help with commercialization there, or if that would be kind of seeking new relationships versus what you guys have now on the retail side for commercializing in Europe? Yeah. Right now, we're primarily focused on driving the consumer side of the business. We're expanding. We're now in 26 different countries, including throughout Europe and including the U.K. Again, there are approximately 140 million babies born around the world, and today, only 3% of those have access to Dream Sock. So we see international as a very large opportunity for us moving forward, and we're exploring various countries and various relationships throughout the world. Very helpful. Thank you, guys. Thank you. We currently have no other questions, so I will pass it over to management for any closing remarks and any other questions that we may have. Yeah. Sorry, we've also received a few relevant questions from investors that we wanted to share during the Q&A. First one is, given the new Amazon partnership signed last year, how much of Q4 2023's Amazon revenue would have been recognized in Q3 2023? Yeah. So just as a reminder to everyone on the call, and alluded to this, but we did sign a new distribution agreement in late Q3 of last year. The impact on last year's Q3 is that we ended up shipping product to Amazon the first week of October. So when we think about comparing year-over-year results, we had about $6 million of net revenue that would have been recognized in Q3 had we been able to ship on time just due to the timing of the agreement. So that was shifted to Q4. So if we adjust for that, the year-over-year growth this quarter would have been about 45%, which is in line with the overall growth trends we're seeing in the business and in our updated guidance for this year. Next question. With all the momentum and opportunities Owlet's seeing, is it possible to get some more color around expectations for 2025? Yeah. I'll grab this. First, our core business is better than it has ever been. We're selling more Dream Socks both domestically and internationally. We're monitoring more babies, capturing more market share than we've ever done before. Secondly, our ability to operate our core business into next year's scale is clear. We're in a very strong position. Our expense profile is in a very good place. We're turning the corner on profitability, and our balance sheet is healthy and strong. We have the right retail partnerships. We have incredible awareness and reach within our consumer base, and we're opening up new healthcare channels. I would just add to that that the opportunity we have with our data set is absolutely immense. We're turning those insights right now into real value through our subscription service. Parents are able to better understand how their child's sleeping, how to get them to sleep longer. We're enabling parents to move kind of that level of care that you see in the office into the home. We expect that's a trend that we'll be able to continue and capitalize on for years to come. We're also, specifically with the launch of subscription, there's real LTV opportunity that we can build over time with the business. Just very excited about 2025 and the years that follow, and we're confident that this is a long-term opportunity. Last one, how should we think about Owlet's revenue seasonality in a typical year? Yeah. In a normal year, Q1 is the lightest quarter. So when we think about our business, babies are born all throughout the year, but the seasonality is truly coming from promotional activity. So for Q1, it's the lightest in terms of promotions. We see the Q2 pick up because of the load-in for Prime Day, which is typically a high-volume, high-discount load-in. So we load in for Prime Day in Q2 to support the promotion that is typically in July. So then from there, Q3 is our seasonally largest revenue for the quarter. We have a lot of activity happening. We have September Baby Safety Month, a load-in for Prime Big Deal Days, which is typically in October. And then most of our retailers load in for holiday during Q3. Then lastly, Q4 comes a little bit down from Q3 just because there's fewer retailers loading in for holiday in Q4. And then what we really see is replenishments in December following the Black Friday, Cyber Monday promotions. That's all the questions we have for today. Please don't hesitate if there's any more that come up post-call. At this time, I'd like to hand the call over to Kurt for some closing remarks. Yeah. I just want to thank everybody for joining the call today. Owlet is leading this category. We've made incredible progress to become a healthier company. We're set up to perform over the long term. We're actively expanding our LTV in the healthcare channels and with subscription. There are subtle changes in the business that are going to have really big impacts over the years to come. And we're just set up with a really unique opportunity to be the leader in infant health. So we're seeing that significant revenue growth right now. We're seeing meaningful margin expansion, and we're supporting all of that with a commitment to drive to profitability and sustainable growth in the future. So we really appreciate everybody's support for the business and for the families that we serve. Thank you so much. Thank you. That will conclude today's call. Thank you for your participation. You may now disconnect the line.